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Abstract
Summary Model-based economic evaluation was performed
to assess the cost-effectiveness of zoledronic acid. Although
zoledronic acid was dominated by alendronate, the incremen-
tal quality-adjusted life year (QALY) was quite small in ex-
tent. Considering the advantage of once-yearly injection of
zoledronic acid in persistence, zoledronic acid might be a
cost-effective treatment option compared to once-weekly oral
alendronate.
Introduction The purpose of this study was to estimate the
cost-effectiveness of once-yearly injection of zoledronic acid
for the treatment of osteoporosis in Japan.
Methods Apatient-level state-transitionmodel was developed
to predict the outcome of patients with osteoporosis who have
experienced a previous vertebral fracture. The efficacy of zo-
ledronic acid was derived from a published network meta-
analysis. Lifetime cost and QALYswere estimated for patients
who had received zoledronic acid, alendronate, or basic
treatment alone. The incremental cost-effectiveness ratio
(ICER) of zoledronic acid was estimated.
Results For patients 70 years of age, zoledronic acid was
dominated by alendronate with incremental QALYof −0.004
to −0.000 and incremental cost of 430 USD to 493 USD.
Deterministic sensitivity analysis indicated that the relative
risk of hip fracture and drug cost strongly affected the cost-
effectiveness of zoledronic acid compared to alendronate.
Scenario analysis considering treatment persistence showed
that the ICER of zoledronic acid compared to alendronate
was estimated to be 47,435 USD, 27,018 USD, and 10,749
USD per QALY gained for patients with a T-score of −2.0,
−2.5, or −3.0, respectively.
Conclusion Although zoledronic acid is dominated by
alendronate, the incremental QALY is quite small in extent.
Considering the advantage of annual zoledronic acid treat-
ment in compliance and persistence, zoledronic acid may be
a cost-effective treatment option compared to alendronate.
Keywords Cost-effectiveness analysis . Fracture prevention .
Health economics . Osteoporosis . Zoledronic acid
Introduction
Among the osteoporotic fractures, hip fracture in particular
imposes not only a clinical burden on patients by aggravating
their QOL and health outcomes but also a significant socio-
economic burden of medical expenses for the treatment as
well as a nursing care. Survival rates reported for patients
who have experienced a hip fracture—81, 49, and 26% for
1, 5, and 10 years, respectively—are lower than rates for the
general population [1]. Also, a health-related QOL score (util-
ity value) of patients in the year following a hip fracture was
reduced by 11.5% compared to the baseline [2]. According to
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a national medical expenditure survey by the Japanese
Ministry of Health, Labor andWelfare, bone density and bone
structure as well as fracture-related expenditure in the popula-
tion aged 65 and over were estimated to be 891.5 billion JPY
in 2012 and 943.6 billion JPY in 2013 [3].
As anti-osteoporosis drugs have become widely used, the
incidence rate of hip fracture has declined in the USA and
Europe; however, it is still on the rise in Japan. A national
survey of hip fractures estimated new fractures at 148,100
(male, 31,300; female, 116,800) in 2007 and 175,700 (male,
37,600; female, 138,100) in 2012, an increase of about 27,600
in 5 years [4, 5]. As the Japanese population ages, the mount-
ing burden caused by the increased incidence of osteoporotic
fractures is of grave concern.
Drug therapy is considered to be an effective measure
against the burden incurred by osteoporotic fractures, and a
wide variety of options are available today. Zoledronic acid is
a bisphosphonate that showed preventive efficacy on osteopo-
rotic fractures in HORIZON-PFT (Pivotal Fracture Trial), a
large population-based randomized trial conducted overseas
[6]. One of the major issues with osteoporosis is the low rate
of patients receiving treatment. According to the in-country
report, the prescription rate for osteoporotic drugs in patients
who experienced a hip fracture was 18.7%, while those who
had no treatment was 53.3%, suggesting that the number of
patients receiving treatment is insufficient [7]. A yearly intra-
venous injection of zoledronic acid is expected to facilitate
long-term treatment for patients and avoid the adverse effects
caused by oral bisphosphonates that require daily, weekly, or
monthly dosing.
Although the drug therapy for osteoporosis definitely re-
duces the risk of fracture and is anticipated to reduce the total
treatment cost for osteoporotic fracture, there is the possibility
of an increase in the total cost of medication. Recently, the
cost-effectiveness of various drug therapies for osteoporosis
has been studied in advanced countries, and the results are
having an effect on decision-making in clinical practice as
well as on healthcare policies. A health economic evaluation
of zoledronic acid conducted in Finland, Norway, and Holland
by Akehurst and colleagues reported that zoledronic acid is
cost-effective compared with basic treatment (placebo, calci-
um, and vitamin D) or other existing bisphosphonates [8].
In Japan, cost-effectiveness of alendronate therapy in
osteopenic women has been examined. The results indicated
that osteoporosis treatment should be considered only for a
high-risk population on the basis of age, bone mineral density
(BMD), and number of clinical risk factors [9]. However, to
date, no health economic evaluation of the drug therapy in-
cluding zoledronic acid for postmenopausal women with os-
teoporosis and with a history of fracture has been reported in
Japan. In addition, there are epidemiological characteristics of
a lower incidence rate of hip fracture [10, 11] and a higher
incidence of vertebral fracture [12, 13] in Japanese compared
to Western people. The Japanese healthcare system also dif-
fers from that of Europe and USA including the drug prices,
treatment fees, and socially acceptable thresholds of the incre-
mental cost-effectiveness ratio (ICER). For these reasons, di-
rect application of the results of studies inWestern countries to
the Japanese population is problematic. The objective of this
study was to estimate the cost-effectiveness of zoledronic acid
in Japanese women with osteoporosis who have experienced a




A model-based, cost-effectiveness analysis was conducted to
evaluate the cost-effectiveness of zoledronic acid plus basic
treatment (once-a-year injection of zoledronic acid 5 mg +
calcium + vitamin D supplement) compared with alendronate
plus basic treatment (once-weekly alendronate 35 mg + calci-
um + vitamin D supplement) or basic treatment alone (calci-
um + vitamin D supplement) in Japanese women with osteo-
porosis having a history of vertebral fracture. We targeted
Japanese women having osteoporosis with a vertebral fracture
as a hypothetical cohort. The base case was a 70-year-old
women with a femoral neck BMD T-score of −2.5
(=0.565 g/cm2). In this model, the T-score is based on the
young adult mean (0.79 ± 0.09 g/cm2) used in a study by
Soen et al., i.e., T-score − 2.5 = (0.565–0.790) / 0.09 [14].
Cohort-based Markov models have been frequently used
for economic evaluation of osteoporotic interventions.
However, this modeling approach is limited by the
Bmemoryless^ feature of the process, which is known as the
Markov assumption [15]. This assumption means that once a
patient has moved from one state to another, the model will
have Bno memory^ regarding where the patient came from.
When transition probabilities depend on prior events (ex: prior
fracture event), this Bmemory^ should be reflected in the mod-
el. To overcome the Bmemoryless^ feature of the Markov
process, we developed a patient-level state-transition model
to predict long-term costs and quality-adjusted life years
(QALYs) associated with each therapy. The seven medical
events (post vertebral fracture; post vertebral and hip fracture;
post vertebral and other fracture; post vertebral, hip, and other
fracture; bedridden; and death) used in the model are shown in
Fig. 1. In this model, Bother fracture^ is defined as a proximal
humeral or distal radius fracture. Also, vertebral fracture in
this model refers to clinical vertebral fracture; morphological
vertebral fracture was not considered. In this model simula-
tion, subjects started with in the state of having a history of
vertebral fracture and faced with various risks of fracture de-
pending on their age, femoral neck BMD, and treatment
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received. The cycle length of the model was defined as 1 year.
During each cycle of the simulation, subjects experienced one
of nine clinical events (no event; vertebral fracture; hip frac-
ture; other fracture; vertebral and hip fracture; vertebral and
other fracture; hip and other fracture; vertebral, hip, and other
fracture; death). In the case of the occurrence of a fracture, the
patient health status was changed to post fracture with an
additional risk for subsequent fractures. We assumed that a
certain number of subjects having a hip fracture would attain
Bbedridden^ status. The model was developed and analyzed
using TreeAge Pro 2016 (TreeAge Software, Williamston,
MA, USA).
Transition probabilities
A transition probability on a fracture event and death was
calculated using the declining exponential approximation of
life expectancy (DEALE) method based on the incidence rate
derived from published sources. In the case of using an expo-
nential function for the distribution, probability (p) of an event
occurring over a time interval (t) was calculated using inci-
dence rate (r) according to the following formula: p-
= 1 − exp.(−rt) [15].
We developed equations for age and a femoral neck BMD-
specific fracture rate using a series of methods developed by
De Laet and colleagues [16] and epidemiological data of
Japanese women with osteoporosis or osteopenia. We first
developed equations for the age-specific fracture rate for hip
and vertebral fractures by using data on fracture rates of
Japanese women and curve-fitting techniques [13, 17, 18].
An exponential curve was created using Stata14 (StataCorp
LP, College Station, TX, USA), while exponential and sig-
moid functions were used for hip and vertebral fractures,
and other fractures, respectively, from the perspective of
Akaike information criterion (AIC) values of approximate ex-
pression and clinical relevance.
Following the method suggested by De Laet and col-
leagues, we formulated an equation for age- and BMD-
specific fracture on the basis of the age-specific fracture rate
in Japan, BMD distributions of femoral neck BMD by age
group, and relative risk (RR) of fracture per 1 SD reduction
in BMD (see supplementary material S-1) [13, 16–19]. The
process of formulating the equation is shown in the S-2.
Incident rates of subsequent fractures for those with a precious
fracture were calculated by multiplying the age- and BMD-
specific fracture rate by the RR of subsequent fracture (S-3)
[20]. For those who have a number of fractures, risk was
calculated by multiplying by the RR more than once (S-3)
[20]. The RR of fracture for those who have a risk factor
independent of BMD was estimated by combining overseas
meta-analysis and national epidemiological data (S-3)
[21–24]. Incident rates of fractures when receiving treatment
was calculated in the same manner by multiplying the formu-
lated equation for fracture incidence rate by the RR of each
fracture (S-3) [6]. In this study, we considered only symptom-
atic clinical vertebral fractures and did not include
Fig. 1 Model structure. Vert
vertebral, Fx fracture
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morphometric vertebral fractures in the model. The proposi-
tion of clinical vertebral fractures among all vertebral fractures
was assumed to be 30% (S-3) [25].
The age-specific mortality rate was obtained from a simpli-
fied life table reported in 2014 by the Ministry of Health,
Labor and Welfare in Japan [26]. The odds ratio for death
10 years after hip fractures was formulated by the curve-
fitting derived from the data reported by Tsuboi et al. (S-1)
[1]. The mortality rate for subjects who experienced a hip
fracture was calculated by multiplying the mortality from the
life table by the aforementioned odds ratio equation. The prob-
ability of becoming bedridden after hip fracture was derived
from a published source in Japan (S-3) [27].
Efficacy of treatment
In the zoledronic acid arm, treatment consisted of 3 years of
zoledronic acid intravenous injection at a dosage of 5 mg per
year. According to the HORIZON-PFT details, the subjects in
both arms received calcium and vitamin D [6]. In the
alendronate arm, patients received once-weekly oral
alendronate therapy at a dosage of 35 mg per week. The frac-
ture risk reduction effect of zoledronic acid and alendronate
was derived from a recently published network meta-analysis
[28]. We modeled the residual effects of zoledronic acid and
alendronate, assuming a linear decline in efficacy of fracture
risk over 3 years, after 3 years of drug treatment (S-3) [29]. In
the model for the base case analysis, full compliance with
zoledronic acid and alendronate treatment was assumed.
Influenza-like symptoms (acute phase reaction) are suggested
as an adverse event of zoledronic acid; however, low- to mid-
level symptoms are considered transient, disappearing within
about 3 days. Given that the adverse events from zoledronic
acid on QOL, outcome of patients, and cost are limited, they
were not considered in this model. Additionally, adverse
events associated with alendronate therapy were not consid-
ered because their impact on long-term costs and clinical ben-
efits was relatively small. We assumed that patients either in
the zoledronic acid arm or in the alendronate arm who expe-
rienced a secondary fracture will continue preventive zoledro-
nic acid therapy or alendronate therapy unless their status is
changed to Bbedridden.^
Costs
We considered medical costs and nursing care costs from the
perspective of the Japanese healthcare and nursing care system.
Supplementary material S-4 summarizes input values for cost
parameters used in the model. All costs were calculated in
Japanese yen (JPY) and converted to US dollars (USD) at the
currency rate of 1 USD = 120 JPY. The annual treatment cost of
zoledronic acid was calculated using the Japanese national drug
pricing standard (39,485 JPY) plus consulting fee (470 JPY)
[30, 31]. Costs for alendronate, calcium, and vitamin D were
based on the Japanese national price list for drugs [32]. Annual
medical cost estimations were based on standard clinical prac-
tice in Japan [27, 31]. In each arm, patients were assumed to see
a doctor every 2 months and having bone metabolism and bone
density measured twice a year (using dual-energy x-ray absorp-
tion). Medical costs due to a fracture event were obtained from
published sources in Japan, which were then adjusted to be
closer in value to the most recent medical fees using a past
revision rate [33–35]. For bedridden patients, we used data
for patients provided with nursing care level 5 under the
Nursing Care Insurance Scheme in Japan [36].
Utilities
Values input for QOL parameters used in the model are sum-
marized in the S-4. The estimating equation to determine the
QOL value for event-free subjects by age group was devel-
oped using linear regression analysis based on the EQ-5D-3L
descriptive system for Japanese elderly people [37]. The QOL
value for patients who experienced fracture events was calcu-
lated by multiplying the event-free QOL value by the percent
reduction in QOL associated with fracture events. Decrease in
the rate of QOL between the first year after experiencing a
fracture and the subsequent years was calculated based on
reported values by the EQ-5D-3L for patients with osteopo-
rotic fractures [2]. Given the lack of data on QOL values for
bedridden patients, to obtain the estimated values, we used
QOL values for patients with nursing care level 5 based on a
national research report [38].
Base case analysis
A Monte Carlo simulation using mean cost and mean QALY
of a hypothetical cohort of 1000 people was performed with
1000 iterations to estimate lifetime expected costs and expect-
ed QALY for the zoledronic acid arm, for the alendronate arm,
and for the basic treatment arm. An annual discount rate of 2%
was applied to both cost and benefit [39]. Based on the esti-
mated expected costs and expected QALY, the incremental
cost-effectiveness ratio (ICER) was estimated as an indicator
of cost-effectiveness using the following formula:
ICER = (Costdrug therapy – Costcomparator) / (QALYdrug
therapy – QALYcomparator). A willingness to pay (WTP) thresh-
old of 50,000 USD per QALY gained was used as the accept-
able level for ICER. We also estimated the incremental net
monetary benefit (INMB) as another indicator of cost-effec-
tiveness, assuming a WTP threshold of 50,000 USD per
QALY ga i n e d , u s i n g t h e f o l l ow i n g f o rmu l a :
WTP × (QALYdrug therapy – QALYcomparator) − (Costdrug
therapy – Costcomparator) [15]. A positive value for INMB indi-
cates that the drug therapy is cost-effective compared to the
comparator at a WTP of 50,000 USD per QALY gained. To
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verify the validity of the simulation, a 10-year probability of
hip and major fractures (hip, vertebral, and others) was calcu-
lated. The simulation was also performed on these populations
with a femoral neck BMD of T-score of −2.0, −2.5, or −3.0
and at 65, 70, or 75 years of age.
Sensitivity analysis
Deterministic sensitivity analyses were performed to examine
the influence of key parameter uncertainties in the model on
the base case analysis. Assessed parameters and ranges are
shown in Supplementary materials S 1, 3, and 4. The plausible
ranges for each parameter were determined based on reported
values, such as 95% confidence interval (CI) in published
sources, or expert opinion.
To estimate a probabilistic distribution of ICER and
perform a probabilistic assessment of the cost-effective-
ness, probabilistic sensitivity analyses was performed
using 1000 iterations of a second-order Monte Carlo
simulation. Probabilistic distribution was determined
based on the modeled parameters that are available in
the published sources, such as 95% CI (S-3). By sam-
pling the value for each parameter from the determined
probabilistic distribution, simulations of the expected
costs, expected QALY and ICER were performed 1000
times. We constructed cost-effectiveness acceptability
curves based on the 1000 iterations of a second-order
Monte Carlo simulation and estimated an acceptable
probability of zoledronic acid treatment from the cost-
effectiveness perspective, assuming a WTP threshold of
50,000 USD per QALY gained.
A scenario analysis was performed to examine the cost-
effectiveness of zoledronic acid by T-score in 70-year-old
patients having one of the following risk factors: current
smoking, high alcohol intake, or a family history of hip
fracture. We also performed a scenario analysis considering
the advantage of once-yearly injection of zoledronic acid
for continuing treatment. In the model for this scenario
analysis, we assumed that a certain proportion of patients
in zoledronic acid arm or alendronate arm discontinued
their prescribed therapy within the initial cycle and they
received calcium and vitamin D after treatment discontin-
uation as in basic treatment arm. Based on a representative
database comprising longitudinal prescription data, the
proportion of patients who continued drug therapy for over
a year in zoledronic acid arm and alendronate arm was
estimated to be 65.62 and 44.76%, respectively (S-3)
[40]. In addition, we examined the influence of treatment
persistence on the cost-effectiveness of zoledronic acid
with different combinations of the proportion of patients
who continued treatment for over a year in zoledronic acid
arm and alendronate arm.
Results
Base case analysis
The results of the base case analysis are shown in Table 1. For
70-year-old osteoporotic patients with a femoral neck BMD T-
score of −2.5, the respective 10-year probability of hip fracture
and the 10-year probability of major fractures were estimated to
be 2.90 and 17.40% for the zoledronic acid arm, 2.80 and
18.50% for the alendronate arm, and 3.60 and 22.9% for the
basic treatment alone arm. Three years of zoledronic acid treat-
ment followed by 3 years of residual were simulated to have a
19.4% risk reduction in hip fracture (RR = 0.806) and a 24%
risk reduction in major fractures (RR = 0.760) compared to
basic treatment alone. Compared to 3 years of alendronate
treatment followed by 3 years of residual effects, the RR values
for hip fracture and major fractures in the zoledronic acid arm
were estimated to be 1.036 and 0.941, respectively. The
alendronate treatment group showed incremental costs of 210
USD per person and conferred additional QALYs of 0.067
compared to the basic treatment group, resulting in an ICER
of 3143 USD per QALY gained. Zoledronic acid treatment was
dominated by alendronate treatment with incremental QALYof
−0.002 and incremental cost of 430 USD. INMB of zoledronic
acid compared to alendronate was estimated to be −507 USD.
The incremental costs and incremental QALYs of zoledronic
acid compared to alendronate tented to be small with an in-
crease of T-score. Although the incremental QALYs nearly
unchanged by age of patients, the incremental costs showed a
decreasing trend with an increase of patient age. The base case
results indicated that zoledronic acid treatment was dominated
by alendronate and showed an incremental QALYof −0.004 to
−0.000 and an incremental cost of 430 USD to 493 USD,
resulting in an INMB of −411 USD to −665 USD.
Sensitivity analysis
The results of our deterministic sensitivity analyses are
summarized in Fig. 2. The tornado diagram for the
INMB of zoledronic acid compared to alendronate
(Fig. 2) showed that the RR of hip fracture with
zoledronic acid and the annual cost of zoledronic acid had
a relatively strong effect on the estimated INMB. If the RR
of hip fracture with zoledronic acid was equal to 0.34 (lower
limit of 95% CI), the zoledronic acid incurred an additional
cost of 98 USD per person and conferred an additional
0.016 QALY compared to alendronate, which resulted in
an INMB of 719 USD and an ICER of 5890 USD per
QALY gained. Assuming the lower cost of zoledronic acid
(−30%), the alendronate incurred an additional cost of
247 USD per person and conferred an additional 0.002
QALY, which resulted in an ICER of 159,760 USD per

































































































































































































































































































































































































































































































































































































































































































































































































































































































































USD). In this case, zoledronic acid becomes a cost-effective
option compared to alendronate applying a WTP of 50,000
USD per QALY gained.
The results of the probabilistic sensitivity analysis were
used to construct the cost-effectiveness acceptability curves
shown in S-5, and the probability of zoledronic acid of being
cost-effective was estimated according to the level of BMD,
assuming that the WTP threshold is 50,000 USD per QALY
gained. The probability that zoledronic acid treatment is the
most cost-effective option for patients with a T-score of −2.0,
−2.5, or −3.0 were estimated to be 7.5, 9.7, or 12.9%, respec-
tively. The probability that the alendronate becomes most
cost-effective option ranged from 87.1 to 91.2% with a WTP
of 50,000 USD per QALY gained.
The results of the scenario analysis considering addi-
tional risk factors are shown in S-6. The scenario analyses
for the INMB of zoledronic acid compared to alendronate
indicated that the INMB of zoledronic acid was below 0
USD in those who have an additional risk factor and be-
came lower in higher-risk group (S-6). The results of the
scenario analysis considering treatment persistence are
shown in Tables 2 and 3. If we assumed that the propor-
tion of patients who continued treatment for over a year
was 65.62% for zoledronic acid arm and 44.76% in
alendronate arm, the ICER of zoledronic acid compared
to alendronate was estimated from 7576 USD to 48,865
USD per QALY gained (Table 2). If zoledronic acid was
expected to improve the proportion of patients who con-
tinued drug therapy for over a year by 10% compared
with alendronate, the ICER was ranged from 23,225
USD to 44,940 USD per QALY gained (Table 3). In ad-
dition, the ICER of zoledronic acid compared to
alendronate was less than 24,203 USD per QALY gained,
if zoledronic acid was expected to improve the proportion
of patients who continued treatment for over a year by
20% compared with alendronate (Table 3).
Discussion
In this study, we estimated the cost-effectiveness of zoledronic
acid therapy for Japanese women with osteoporosis and a
history of vertebral fracture using state-transition model. Our
results demonstrate that zoledronic acid therapy for patients
aged 65 and over with a T-score of −2.0 is likely to be dom-
inated by alendronate therapy with quite small difference in
QALYs. Furthermore, we found that zoledronic acid is less
effective and more costly for those patients who have one of

































































































































































































































































































































































































































































































































































































































































































































































































































































































































the risk factors―current smoking, high alcohol intake, and a
family history of hip fracture compared to alendronate. The
perspective of our study is novel in terms of examining the
cost-effectiveness of zoledronic acid using various combina-
tions of age, BMD, and number of clinical risk factors com-
pared with alendronate. To estimate incidence rates of osteo-
porotic fracture in Japanese women, the use of a large cohort-
based fracture risk assessment tool, such as FRAX developed
by WHO, is preferable. However, in building the model, we
did not use FRAX because the algorithm and parameter esti-
mates are not available to the public. In the present study, we
developed original prediction equations for the incidence rate
of fracture based on the epidemiological data published in
Japan. Our model considered the risk of not only hip fracture
and clinical vertebral fracture but also of other osteoporotic
fractures such as proximal humerus and distal radius fractures.
The validity of our prediction equation was verified by com-
parison of the predicted 10-year osteoporotic fracture proba-
bilities in our model with those derived from FRAX [9, 41].
The 10-year index case fracture probabilities in our model
were confirmed to be almost identical to those from FRAX;
thus, we consider this model to assess the cost-effectiveness of
osteoporosis therapy in Japanese women to be appropriate.
The cost-effectiveness of zoledronic acid varies from country
to country. A study in Finland reported that zoledronic acid
dominated alendronate in 50- to 80-year-old patients who have
a history of fracture and a T-score of −2.5 [8]. In a Norwegian
study, zoledronic acid has also been shown to be dominant
(more effective and less costly) compared to alendronate in
patients aged 70 and 80 years; in patients aged 50 and 60 years,
the ICER of zoledronic acid compared with alendronate was
NOK 76,188 and NOK 83,954 per QALY gained, respectively
[8]. In Holland, the ICER of zoledronic acid compared with
alendronate ranged from 36,927 EUR per QALY in patients
aged 60 years to 48,383 EUR per QALY in patients aged
80 years [8]. However, the results of our base case analyses
showed that zoledronic acid was dominated by alendronate.
Several factors are suggested for this gap including the differ-
ences in the fracture risk of baseline, discount rate of cost and
health benefits, fracture treatment costs, and drug costs. One of
the possible reasons for the gap is a setting of efficacy on the RR
for hip fracture. To date, there have been no head-to-head clin-
ical trials with these drugs, and therefore, no evidence for direct
comparison for fracture risk decline has been established.
Hence, we indirectly evaluated the cost-effectiveness of zole-
dronic acid therapy compared to oral alendronate therapy using
the evidence from network meta-analysis. The results of our
base case analyses showed that zoledronic acid was slightly less
effective and costly than alendronate (incremental QALY,
−0.004 to −0.000; incremental cost, 366 to 493 USD).
Zoledronic acid was more effective in preventing major osteo-
porotic fractures (RR = 0.935–0.944) but less effective in
preventing hip fracture (RR = 1.000–1.059) compared to
alendronate. Deterministic sensitivity analyses of our model
indicated that parameters associated with hip fracture had a
relatively strong effect on the cost-effectiveness of osteoporotic
Table 3 Results of sensitivity analysis on proportion of 1-year treatment persistence
Proportion of 1-year persistence for zoledronic acid (%)
90 80 70 60 50 ZOL + BT (vs ALN + BT)
Proportion of 1 year persistence
for alendronate (%)
80 362 344 322 294 244 Incremental cost (USD)
0.008 0.002 −0.004 −0.010 −0.017 Incremental QALYs
44,940 225,388 Dominated Dominated Dominated ICER (USD per QALY)
70 359 340 319 291 240 Incremental cost (USD)
0.015 0.008 0.002 −0.003 −0.010 Incremental QALYs
24,203 41,005 129,970 Dominated Dominated ICER (USD per QALY)
60 370 352 331 302 252 Incremental cost (USD)
0.022 0.015 0.009 0.003 −0.003 Incremental QALYs
17,125 23,317 35,793 86,844 Dominated ICER (USD per QALY)
50 398 380 359 330 280 Incremental cost (USD)
0.029 0.022 0.017 0.011 0.004 Incremental QALYs
13,745 16,933 21,617 30,453 63,877 ICER (USD per QALY)
40 388 370 348 319 269 Incremental cost (USD)
0.036 0.030 0.024 0.018 0.012 Incremental QALYs
10,740 12,481 14,660 17,685 23,225 ICER (USD per QALY)
BT: basic treatment (placebo + calcium + vitamin D), ZOL: once-yearly injection of zoledronic acid 5 mg, ALN: once-weekly oral alendronate 35 mg. 1
USD = 120 JPY (February 2016 exchange rate)
QALYs quality-adjusted life years, ICER incremental cost-effectiveness ratio
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treatments. Based on the published network meta-analysis, the
RR of hip fracture compared to basic treatment was estimated to
be 0.50 in the zoledronic acid arm and 0.45 in the alendronate
arm. Therefore, we consider themain explanation for our results
to be the settings related to hip fracture. The results from the
study in Finland, Norway, andHolland indicated that zoledronic
acid was a cost-effective or cost-saving option compared with
alendronate, which were considerably different from our results
[8]. We consider these gaps to be mainly derived from the
difference in the setting of the RR for hip fracture compared
to basic treatment. They estimated the RR for hip fracture by
zoledronic acid to be 0.59 from the HORIZON-PFTand the RR
by alendronate to be 0.62 from the economic evaluation report-
ed by NICE, assuming that the treatment effect observed in
clinical trials was independent of patient’s baseline risk factors.
Although various studies have used data of the restraining ef-
fects on fractures derived from different sources for model anal-
ysis, we believe that caution is necessary when handling such
data. For an assessment of cost-effectiveness comparing a vari-
ety of treatments, a more appropriate indirect comparison such
as network meta-analysis is required. In our study, we estimated
the comparative effectiveness among multiple osteoporotic
treatments by using a recently published networkmeta-analysis,
whichwe considered to be the best source of available data [28].
However, network meta-analyses generally require advanced
technical skills and thorough understanding. The results vary
depending on the trials included in a syntactic analysis as well
as the timing of the trials. Therefore, caution needs be taken
when using these analyses.
The results of the deterministic sensitivity analysis on pa-
tients with a T-score of −2.5 indicated that a parameter such as
the efficacy of zoledronic acid has a relatively strong impact
on the base case result. If the RR of hip fracture with zoledro-
nic acid was equal to 0.34 (lower limit of 95% CI), the ICER
of zoledronic acid compared to alendronate was 5890 USD
per QALY gained. In other words, judgment of the cost-
effectiveness of zoledronic acid compared to alendronate
may vary if the restraining effect of zoledronic acid on hip
fracture is higher. Our analysis thus suggests that zoledronic
acid treatment might be cost-effective compared to
alendronate for a selected population, that is, one in which
the treatment has a high therapeutic effect. A subgroup anal-
ysis of HORIZON-PET by Eastell et al. indicated that zole-
dronic acid has preventive effects on vertebral fracture in rel-
atively young women with a normal creatinine clearance with
BMI ≥25 kg/m2 [42]. However, they found that background
factors had no statistical significance on the hip fracture pre-
ventive effects [42]. Therefore, using the results of our analy-
sis requires an understanding that the cost-effectiveness of
zoledronic acid is sensitive to the degree of the restraining
effect on hip fracture. Our simulation was based on the annual
drug cost of zoledronic acid which has only recently been
approved in Japan. If the annual drug cost of zoledronic acid
is 30% lower than the set value of 39,485 JPY (329 USD), the
ICER of alendronate compared to zoledronic acid was
159,760 USD per QALY gained. In this case, zoledronic acid
becomes a cost-effective option compared to alendronate ap-
plying a WTP of 50,000 USD per QALY gained.
Probabilistic sensitivity analysis showed that the probabil-
ity of zoledronic acid of being cost-effective in patients with a
T-score of −2.0, −2.5, and −3.0 was 7.5, 9.7, and 12.9% com-
pared with alendronate treatment and basic treatment alone
when using the WTP of 50,000 USD per QALY, respectively.
The probability that alendronate becomes the most cost-
effective option ranged from 87.1 to 91.2% in those patients.
In terms of medical economics, our results suggest that for this
patient group, the use of alendronate is recommended.
The main limitation of our analysis is the assumptions about
compliance and persistence of the treatment. In the base case
analysis of this study, we assumed that there was no difference
in the compliance and persistence between zoledronic acid and
alendronate. However, one of the major issues with osteoporo-
sis is poor adherence and persistence with drug therapies in
clinical practice, which may affect the cost-effectiveness in real
world. Although the real-life compliance and persistence data
of zoledronic acid is not yet available in Japan, it has been
reported that 65.5% of the patients received a second infusion
of zoledronic acid after 1 year, while 44.8% of patients
remained on the weekly oral alendronate treatment in
Germany [40]. Therefore, we performed scenario analysis con-
sidering treatment persistence by using this data. The scenario
analysis showed that zoledronic acid might be a cost-effective
treatment option compared to weekly oral alendronate (ICER,
10,749 USD to 47,435 USD per QALY gained). Furthermore,
we estimated the ICER of zoledronic acid with different com-
binations of the proportion of patients who could continue drug
therapy for over a year in zoledronic acid arm and alendronate
arm. As a result, we found that zoledronic acid might be cost-
effective compared to alendronate if zoledronic acid was ex-
pected to improve the proportion of patients who continued
treatment for over a year by 10% compared to alendronate with
a few exceptions. Recently, Kishimoto and Maehara reported
that the 1 year medication possession ratio (MPR), which was
used as an indicator of compliance, was 70.6% for weekly oral
bisphosphonates in Japan [43]. If we assumed the proportion of
patients who continued therapy for over a year in alendronate
arm was equal to 70% based on the previous report, the cost-
effective threshold for the proportion of treatment persistence
for over a year in zoledronic acid armwas estimated to be about
80% or more. The data obtained from this study will possibly
facilitate decision-making to determine medical practice.
However, comparable data with zoledronic acid or other
bisphosphonates on compliance and persistence are insufficient
at present. The advantage of an annual injection of zoledronic
acid in compliance and persistence in Japanese setting should
be challenges for the future studies.
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Another limitation is that we estimated the efficacy of zo-
ledronic acid treatment based on the network meta-analysis
using a randomized clinical trial that was conducted in coun-
tries other than Japan. A subgroup analysis of HORIZON-
PET indicated that background factors such as race
(Caucasian, Asian, or other) and geographical region
(Europe, Asia, or the Americas) had no statistically significant
effect on the preventive effects of the treatment on osteopo-
rotic fractures [42]. Therefore, we concluded that, to some
extent, extrapolating the preventive effect of zoledronic acid
from the population of HORIZON-PET to Japanese women
would be acceptable. The sensitivity analysis showed that the
uncertainty about the efficacy of zoledronic acid on the RR for
hip fracture had a relatively large impact on the ICER of pre-
ventive zoledronic acid therapy, and therefore, the efficacy of
zoledronic acid in postmenopausal Japanese women with os-
teoporosis should be determined to confirm the validity of our
results. Although the average age of patients in HORIZON-
PETwas 73, we assumed the average age of a patient to be 70
and ranged from 65 to 75 in the base case analysis. The sub-
group analysis showed that for the preventive effects on ver-
tebral fracture, there was a statistically significant difference
between the treatment and the age of patients [42]. Therefore,
the RR of vertebral fracture by zoledronic acid should vary
depending on the age of the patient. However, our sensitivity
analysis showed that the impact of the RR for vertebral frac-
ture from zoledronic acid on the ICER was relatively small.
Therefore, we used a fixed value for the point estimate of the
RR for vertebral fracture from zoledronic acid.
Finally, it is important to note that the cost-effectiveness of
zoledronic acid treatment for Japanese osteoporosis patients
varies depending on the social acceptability of the ICER
threshold. The WTP threshold of 50,000 USD per QALY in
the USA and 20,000–30,000 GBP per QALY in the UK is
commonly acceptable [44, 45]. However, as noted above, it
varies from country to country, and there is no international
consensus. In Japan, a study by Ohkusa and Sugawara has
proposed a WTP threshold of 6,350,000–6,700,000 JPY
(52,917–55,833 USD) per QALY gained [46]. Although still
controversial, the population for which drug treatment is cost-
effective may vary depending on Japanese societal WTP for
an additional QALY.
Conclusion
Although once yearly zoledronic acid treatment in Japanese
osteoporosis patients with a history of vertebral fracture is
dominated by weekly oral alendronate, the difference in effec-
tiveness is quite small in extent. Considering the advantage of
annual zoledronic acid for continuing treatment, zoledronic
acid may be a cost-effective treatment option compared to
alendronate.
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